# Protagonist Therapeutics (PTGX): value investors who own it

1 value investor held Protagonist Therapeutics in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $2.8m | Trimmed -6.9% | 5 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Sold | 46034 | $6.5m |
| 2026-09-30 | Ali Asif | Chief Financial Officer | Sold | 12595 | $1.8m |
| 2026-09-10 | PATEL DINESH V PH D | President and CEO | Sold | 7278 | $1.0m |
| 2026-09-09 | PATEL DINESH V PH D | President and CEO | Sold | 63548 | $9.3m |
| 2026-09-08 | PATEL DINESH V PH D | President and CEO | Sold | 54174 | $7.9m |
| 2026-08-11 | PATEL DINESH V PH D | President and CEO | Sold | 34239 | $5.1m |
| 2026-08-10 | PATEL DINESH V PH D | President and CEO | Sold | 65761 | $9.8m |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/ptgx). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.